Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy
NCT ID: NCT06613321
Last Updated: 2024-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
47 participants
OBSERVATIONAL
2023-08-01
2024-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will include all patients from the hospital, followed for pulmonary hypertension associated with COPD under vasodilator therapy between 2015 and 2021.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Significance of Circulating Microvesicles in Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
NCT05250128
Pulmonaryhypertension in Copd at Different Levels of Smoking
NCT06031311
Change in Airway Peripheral Tone in COPD
NCT04166812
Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD
NCT03110614
Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi
NCT02586883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will include all patients from the hospital, followed for PH associated with COPD under vasodilator therapy between 2015 and 2021.
It will evaluate patients' lung hyperinflation according to the RV/TLC ratio and their response to treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with increased lung distension
Defined by a residual volume over total lung capacity ratio (RV/TLC ratio) above the median value of all included patients.
Respiratory function tests before introduction of vasodilator therapy
Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
3 month follow up evaluation of response to treatment.
Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
Patients without increased distension disorder
Defined by a residual volume over total lung capacity ratio (RV/TLC ratio) below the median value of all included patients.
Respiratory function tests before introduction of vasodilator therapy
Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
3 month follow up evaluation of response to treatment.
Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Respiratory function tests before introduction of vasodilator therapy
Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
3 month follow up evaluation of response to treatment.
Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* thoracic pathology such as kyphoscoliosis
* pleural effusion (unless part of pulmonary veno-occlusive disease)
* a large tumor lung mass
* EFR missing or uninterpretable because difficult to perform
* initiation of calcium channel blockers
* surgical treatment in chronic thrombo-embolic pulmonary hypertension
* no follow-up evaluation (lost to follow-up or died before reassessment)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ari Chaouat, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Université de Lorraine, Département de Pneumologie, CHRU NANCY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Farkouh C, Chaouat A, Guillaumot A, Baptista BR, Chabot F, Valentin S. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: Impact of lung hyperinflation on the response to pulmonary hypertension treatment. Respir Med Res. 2025 May;87:101153. doi: 10.1016/j.resmer.2024.101153. Epub 2024 Dec 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023PI014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.